Matthias M. Weber

Johannes Gutenberg University Mainz — Germany

Medicine · Health Sciences

43h-index6.2kcitations257works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Growth Hormone and Insulin-like Growth Factors(54), Neuroendocrine Tumor Research Advances(38), Lung Cancer Research Studies(28), Neuroblastoma Research and Treatments(27), Pituitary Gland Disorders and Treatments(24)

Publications256 total

Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population
European Journal of Heart Failure·2025· 3 citedOpen Access
Imaging-derived biomarkers from 68Ga-DOTATOC PET/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with 177Lu-DOTATATE
Cancer Imaging·2025Open Access
Supplementary Table S1 from Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)
2025Open Access
Data from Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)
2025Open Access
Adult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER)
Journal of the Endocrine Society·2025· 1 citedOpen Access
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Journal of Nuclear Medicine·2025· 17 citedOpen Access
Impact of type 2 diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis
PLoS ONE·2025Open Access
Neuroendokrine Neoplasien (NEN)
2025
Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)
Clinical Cancer Research·2024· 7 cited
SAT-694 Long-term Effectiveness And Safety Of GH Replacement Therapy In Adults &amp;lt;60 Years: Real-world Data From NordiNet® IOS And ANSWER
Journal of the Endocrine Society·2024Open Access
FRI-120 Impact of diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis
Journal of Hepatology·2024
Autoren
Elsevier eBooks·2024Open Access
Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN)
Elsevier eBooks·2024
1185MO Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials
Annals of Oncology·2023· 9 citedOpen Access
Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
Journal of the Endocrine Society·2023· 10 citedOpen Access
Reduktion der Messzeitpunkte bei prätherapeutischer Organdosimetrie metastasierter NET vor PRRT
Nuklearmedizin - NuclearMedicine·2023
Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
Endocrine Connections·2022· 7 citedOpen Access
Second MAFA Variant Causing a Phosphorylation Defect in the Transactivation Domain and Familial Insulinomatosis
Cancers·2022· 12 citedOpen Access
Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
Cancers·2022· 18 citedOpen Access
Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN)
Elsevier eBooks·2021
page 1 of 13Next →

Frequent Co-authors

Christian Fottner(15), Thomas Först(7), Eckhard Wolf(6), Arno Schad(6), Andreas Pfützner(6), D. Engelhardt(5), Thomas J. Musholt(5), Mathias Schreckenberger(4), Matthias Miederer(4), Heiko Zimmermann(3), Peter J. Feilen(3), Stephan Schneider(3), U. Zimmermann(3), Andreas Hoeflich(3), Harald Lahm(3), Dieter Engelhardt(3), Peter R. Galle(3), Martina Ferrata(3), Hauke Lang(3), Martin W. Elmlinger(2)